Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Kepler Capital Stick to Their Hold Rating for Grifols SA

Published 12/21/2021, 04:17 AM
Updated 12/21/2021, 04:17 AM


Kepler Capital analyst Arnaud Girod maintained a Hold rating on Grifols SA (NASDAQ:GRFS) on Wednesday, setting a price target of EUR22.9, which is approximately 141.03% above the present share price of $10.72.

Girod expects Grifols SA to post earnings per share (EPS) of $0.20 for the fourth quarter of 2021.

The current consensus among 2 TipRanks analysts is for a Hold rating of shares in Grifols SA, with an average price target of $24.2.
The analysts price targets range from a high of $25.84 to a low of $22.57.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.35 billion and a net profit of $244.2 million. The company's market cap is $9.47 billion.

According to TipRanks.com, Kepler Capital analyst Arnaud Girod is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.5% and a 52.15% success rate.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.